BHRT vs Conventional HRT: Understanding the Differences That Matter

Patients researching hormone replacement therapy encounter two broad categories: conventional HRT and bioidentical hormone replacement therapy (BHRT). The terminology can be confusing, and the distinction is often oversimplified. A clear understanding of how these approaches differ, and where they overlap, supports better decision making.

Molecular Identity

The most fundamental difference is molecular structure.

Bioidentical hormones are molecularly identical to the hormones produced by the human body. Bioidentical estradiol is the same estradiol your ovaries produce. Bioidentical testosterone is the same testosterone your testes or adrenal glands synthesize. The body recognizes and metabolizes these molecules through its native enzymatic pathways.

Conventional HRT includes hormones that are structurally different from human hormones. Conjugated equine estrogens (Premarin), derived from pregnant mare urine, contain a mixture of estrogens, some of which are not found in the human body. Medroxyprogesterone acetate (Provera), a synthetic progestin, differs structurally from the progesterone produced by the corpus luteum.

This molecular distinction matters. The body processes bioidentical hormones through the same pathways it uses for its own production. Synthetic and non-human hormones are metabolized differently, which can influence both efficacy and side effect profiles.

The Nuance Worth Noting

Not all conventional HRT is non-bioidentical. Several commercially manufactured, Health Canada approved products contain bioidentical hormones. Estrace (oral micronized estradiol), Estrogel (transdermal estradiol), and Prometrium (micronized progesterone) are all bioidentical in molecular structure and available through standard pharmacies.

The distinction, then, is not simply branded versus compounded. It is about whether the hormone molecule matches human physiology, whether the delivery method is optimized for the individual, and whether the protocol is standardized or personalized.

Standardization vs Individualization

Conventional HRT is typically prescribed in fixed doses using commercially available formulations. A patient might receive 1 mg of oral estradiol or a 0.05 mg/day estrogen patch. These are effective starting points, but the dose increments are limited to what the manufacturer produces.

BHRT, particularly when compounded, allows for precise dose customization. A compounding pharmacy can prepare a cream at exactly the concentration a patient needs, adjusted in small increments based on lab results and clinical response. This granularity is especially valuable when titrating hormones to optimal levels rather than simply reaching a standard therapeutic range.

For patients whose symptoms persist at standard doses, or who experience side effects that a slight dose adjustment might resolve, compounded BHRT offers a precision that fixed dose products cannot match.

Delivery Methods

Conventional HRT is available in oral tablets, transdermal patches, and vaginal preparations. These are well studied and widely used.

Compounded BHRT expands the options. Transdermal creams and gels can be formulated at custom concentrations. Troches (sublingual lozenges) provide an alternative absorption route. Injectable formulations, including testosterone cypionate and enanthate, allow for precise dosing on defined schedules. Vaginal and rectal compounds can be prepared when local delivery is preferred.

The delivery method influences absorption, metabolism, and hormone levels throughout the day. A physician experienced in BHRT selects the route that best serves the patient’s physiology, lifestyle, and goals.

Progesterone Deserves Particular Attention

The difference between bioidentical progesterone and synthetic progestins is one of the most clinically significant distinctions in hormone therapy.

Micronized progesterone (bioidentical) has been studied extensively. The French E3N cohort study, among others, found no increase in breast cancer risk with micronized progesterone compared with synthetic progestins,¹ and micronized progesterone has a more neutral effect on lipids and cardiovascular markers than many synthetic progestins.²

Synthetic progestins such as medroxyprogesterone acetate activate progesterone receptors but also interact with other steroid receptors in ways that micronized progesterone does not.³ This difference in receptor selectivity has meaningful clinical implications.

For women requiring progesterone as part of their hormone therapy, the choice between bioidentical progesterone and a synthetic progestin is one that deserves careful, informed discussion with their physician.

Monitoring Philosophy

Conventional HRT prescribing often follows a symptom driven approach: prescribe a standard dose, assess symptom relief at follow up, adjust if needed. Bloodwork may be ordered periodically but is not always central to ongoing management.

BHRT practiced within a functional medicine framework places laboratory monitoring at the centre of care. Baseline bloodwork establishes where the patient starts. Follow up panels, typically at 8 to 12 week intervals during optimization, confirm that hormone levels are reaching the therapeutic range, that metabolites are being processed safely, and that downstream markers such as lipids, liver function, and hematocrit remain within acceptable limits. Body composition assessment—particularly the distinction between visceral and subcutaneous fat—is tracked across the treatment course to ensure that hormonal optimization is not simply reducing symptoms but is shifting the metabolic substrate toward healthier phenotypes.

This monitoring intensive approach reflects a core principle: measure, intervene, measure again. Adjustments are driven by objective data, correlated with how the patient feels and how their body performs.

Safety and the Evidence Base

The Women’s Health Initiative (WHI), published in 2002, shaped a generation of caution around hormone therapy. It is worth understanding what that study actually tested: oral conjugated equine estrogens combined with medroxyprogesterone acetate in a population with an average age of 63.⁴

Subsequent analyses, including the WHI’s own age stratified data, indicate that the risk profile differs when therapy is initiated closer to menopause,⁵ and observational data show that transdermal delivery, which bypasses first pass hepatic metabolism, does not carry the venous thromboembolism risk of oral estrogen.⁶

The molecule matters as well as the route. Even among oral preparations, estradiol is not equivalent to conjugated equine estrogens: a JAMA Internal Medicine analysis found roughly double the venous thrombosis risk with oral conjugated equine estrogens compared with oral estradiol,⁷ and a large BMJ study confirmed that estradiol carried a lower thromboembolism risk than conjugated equine estrogens, with transdermal preparations carrying no measurable excess risk at all.⁸

The Endocrine Society, the North American Menopause Society, and the International Menopause Society have all published position statements supporting hormone therapy when initiated within the appropriate window and individualized to the patient.

BHRT is not alternative medicine. It is a refinement of hormone therapy that uses molecules identical to human physiology, delivered in individualized doses, and monitored with precision.

How to Choose

The right approach depends on the patient.

For some, a commercially available bioidentical product such as an estradiol patch and oral micronized progesterone is entirely sufficient. The dose is appropriate, the delivery is convenient, and the results are excellent.

For others, the fixed dose options do not produce optimal results, or the patient’s hormonal profile requires a more nuanced protocol. Compounded BHRT, prescribed by a physician with advanced training and monitored through comprehensive bloodwork, provides the additional precision these patients need.

The goal is not to choose a category. The goal is to find the approach that restores optimal function for the individual. A physician experienced in both conventional and bioidentical hormone therapy can guide that decision based on clinical evidence, laboratory data, and the patient’s own experience.

Questions Worth Asking Your Physician

Patients exploring their options benefit from asking direct questions.

What is the molecular structure of the hormone you are prescribing? Is it identical to what my body produces? What delivery method do you recommend, and why? How will you monitor my levels and adjust my protocol? What is your training and experience with hormone optimization? Do you use a structured framework to measure my progress over time?

The answers will reveal whether the physician’s approach is standardized or individualized, and whether the practice is oriented toward symptom management or true optimization.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Bioidentical Hormone Therapy in Ontario: A Physician’s Guide
• What the WHI Got Wrong
• Hormone Therapy and Breast Cancer Risk

References

1. Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008. PMID: 17333341
2. Fitzpatrick LA, et al. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril. 1999. PMID: 10519605
3. Campagnoli C, et al. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005. PMID: 16249080
4. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002. PMID: 12117397
5. Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007. PMID: 17405972
6. Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007. PMID: 17309934
7. Smith NL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014. PMID: 24081194
8. Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019. PMID: 30626577

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.